前列腺癌靶向、病灶周围及远端活检的前瞻性研究
MIRAGE 是在欧洲十中心开展的前瞻性观察研究,纳入 912 例 PI-RADS≥3 单病灶男性,强制靶向加病灶周围活检、远端活检由研究者决定。结果显示病灶周围采样使 GG≥2 检出率增加 3.6%,代价是 GG1 增加 1%;远端采样增量有限,应省略。
要点
- 靶向加病灶周围活检策略下,病灶周围采样使 GG≥2 检出率增加 3.6%。
- 病灶周围采样的最大获益见于初次活检者和 PI-RADS 4-5 病灶者。
- 远端采样对 GG≥2 增量仅 1.4%-1.6%,却增加更多 GG1,应省略。
核心结论
- 靶向加病灶周围活检策略下,远端活检诊断增益极小,应省略。
研究设计与样本
- MIRAGE 为前瞻性、观察性、多中心研究,2025 年 1-6 月在十个欧洲中心开展,纳入 912 例 PI-RADS≥3 单病灶男性。
- 靶向和病灶周围活检为强制,远端活检由研究者决定。
主要发现
- 靶向活检在 380 例(41%)男性中检出 GG≥2 病灶。
- 与单独靶向活检相比,病灶周围采样使 GG≥2 检出率增加 3.6%,GG1 检出率增加 1%。
- 病灶周围采样最大获益见于初次活检者和 PI-RADS 4-5 病灶者;PI-RADS 3 或既往阴性活检者中,病灶周围采样检出的 GG1 多于 GG≥2。
- 远端采样对 GG≥2 的增量:对侧 +1.6%,同侧 +1.4%;对 GG1 的增量:对侧 +2.5%,同侧 +2.9%。
临床怎么用
- 对 PI-RADS≥3 单病灶男性,采用靶向加病灶周围活检策略,可省略远端活检。
- 初次活检者和 PI-RADS 4-5 病灶者从病灶周围采样中获益最大。
- PI-RADS 3 或既往阴性活检者,病灶周围采样可能增加 GG1 检出,需权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Targeted plus perilesional biopsies are recommended for men with prostate lesions visible on magnetic resonance imaging. However, available data are mainly retrospective, without predefined biopsy scheme protocols. The MRI-Integrated Regional and targeted Approach, recommendations, and Guidelines for prostate biopsies (MIRAGE) study is the first prospective European study designed to evaluate the outcomes when perilesional biopsies are incorporated deliberately into the biopsy protocol. METHODS: MIRAGE was a prospective, observational, multicenter study conducted across ten European centers between January and June 2025. We enrolled 912 men with a single Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesion. Targeted and perilesional biopsies were mandated, while distant biopsies (ie, cores taken beyond the perilesional zone) were left to the discretion of investigators. Detection rates of Gleason grade (GG) group ≥2 and 1 lesions were calculated separately for each scheme: targeted, perilesional, and distant biopsies. KEY FINDINGS AND LIMITATIONS: Targeted biopsy detected GG group ≥2 lesions in 380 men (41%). Compared with targeted biopsy alone, perilesional sampling increased GG group ≥2 lesion detection by +3.6% at the cost of +1% GG group 1 lesion detection. The greatest benefit of perilesional sampling was observed in biopsy-naïve men and those with PI-RADS 4-5 lesions. Conversely, in those with PI-RADS 3 or a prior negative biopsy, perilesional sampling yielded more cases of GG group 1 than of GG group ≥2. Distant sampling provided minimal incremental GG group ≥2 (contralateral: +1.6%; ipsilateral: +1.4%) but more GG group 1 (contralateral: +2.5%; ipsilateral: +2.9%) cases. CONCLUSIONS AND CLINICAL IMPLICATIONS: The MIRAGE study provides prospective evidence that, when a targeted plus perilesional biopsy strategy is applied, distant biopsies add minimal diagnostic benefit and should be omitted.
引用
- Baboudjian M, Uleri A, Anract J, et al. Targeted, Perilesional, and Distant Biopsies in Prostate Cancer. Eur Urol Oncol. 2026. PMID: 41735130. doi:10.1016/j.euo.2026.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。